[An approach to the preparation of digestive enzyme-drug for oral administration: enteric-soluble disaccharidase microcapsules].
For the purpose of replacement therapy in cases of disaccharide intolerances, yeast disaccharidases were prepared as enteric-soluble microcapsules to prevent their inactivation by gastric juice and alimentary proteases. The enteric-soluble microcapsules have a mean diameter of 0.544 +/- 0.058 mm. Following encapsulation, activity recoveries for invertase and lactase were 84.4 +/- 10.6% and 70.1 +/- 5.5%, respectively. Over 55% of the remaining microcapsulated disaccharidase activity was retained in artificial gastric juice during 2 h of coincubation. Over 90% of the enzyme activity was released from the microcapsules within 1 h in artificial intestinal juice.
Wang
X
X
Zhejiang Branch, Hangzhou.
D002214:Capsules; D004186:Disaccharidases / Q000737:chemistry; D004355:Drug Stability; D006026:Glycoside Hydrolases / Q000032:analysis; D043322:Lactase; D013608:Tablets, Enteric-Coated; D013678:Technology, Pharmaceutical; D043324:beta-Fructofuranosidase; D001616:beta-Galactosidase / Q000032:analysis
D002214:Capsules; D013608:Tablets, Enteric-Coated; D004186:Disaccharidases; D006026:Glycoside Hydrolases; D043322:Lactase; D001616:beta-Galactosidase; D043324:beta-Fructofuranosidase